Related Experiment Video
Updated: Jul 14, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
Fabienne Ory-Magne1, Christine Brefel-Courbon1, Marion Simonetta-Moreau1
1Department of Neurology, University Hospital CHU, Toulouse, France.
Summary
Age influences quality of life outcomes after subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) patients. Older patients showed less improvement in daily activities and cognition 24 months post-STN-DBS.
Area of Science:
- Neurology
- Neurosurgery
- Gerontology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Subthalamic nucleus deep brain stimulation (STN-DBS) is a therapeutic option for advanced PD.
- The impact of patient age on STN-DBS outcomes requires further elucidation.
Purpose of the Study:
- To investigate the influence of aging on clinical, cognitive, and quality-of-life outcomes following STN-DBS in Parkinson's disease patients.
- To correlate age with motor function, mood, cognition, and quality of life improvements at 12 and 24 months post-surgery.
- To assess the relationship between age and adverse events, specifically cerebral bleeding risk.
Main Methods:
- Prospective study of 45 Parkinson's disease patients undergoing STN-DBS.
- Motor assessment (UPDRS), mood, cognitive, and quality of life (PDQ-39) evaluations pre-surgery and at 12 and 24 months post-surgery.
- Regression analysis to correlate age with outcome variations; nonparametric test for cerebral bleeding risk.
Main Results:
- No significant correlation between age and motor or PDQ-39 improvements at 12 months.
- At 24 months, older age negatively correlated with improvements in PDQ-39 dimensions: mobility, activities of daily living, and cognition.
- Apathy and depression showed a positive correlation with age; a significant difference in cerebral bleeding risk was observed with age.
Conclusions:
- STN-DBS demonstrates efficacy in elderly Parkinson's disease patients.
- Age significantly impacts long-term quality of life, particularly in mobility, daily activities, and cognitive domains, 24 months after STN-DBS.
- Further research with longer follow-up and larger cohorts is needed to refine understanding of age-related quality of life perception and hemorrhage risk in STN-DBS for PD.
More Related Videos
07:14A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
06:32Bringing the Clinic Home: An At-Home Multi-Modal Data Collection Ecosystem to Support Adaptive Deep Brain Stimulation
Published on: July 14, 2023
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...